Cytori Therapeutics to Participate in Stem Cell Therapy Focus Session at the BIO CEO & Investor Conference
Posted on: Thursday, 9 February 2006, 18:00 CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX)(Frankfurt:XMPA) announced today that Marc H. Hedrick, M.D., President of Cytori Therapeutics, will participate in a focus session entitled, "Cell Therapy: Getting Around the Embryonic Stem Cell Issue," on Wednesday, February 15, 2006 from 3:30 p.m. to 4:55 p.m. Eastern Standard Time, at the Biotechnology Industry Organization (BIO) CEO & Investor Conference, in New York City, NY.
The focus panel will examine how companies are translating technological breakthroughs in stem cell research into innovative treatments. The session will be moderated by Michael Werner, Esq., President at The Werner Group. The panelists in addition to Dr. Hedrick are Reni Benjamin, Senior Biotechnology Analyst, Rodman & Renshaw, LLC; Mr. Bruce Cohen, President and CEO, Cellerant Therapeutics, Inc.; Dr. Thomas Okarma, President and CEO, Geron Corporation and Mr. James Stewart, Senior Vice President and CFO, Advanced Cell Technologies.
The focus session will be webcast live and may be accessed through the Company's website at http://ir.cytoritx.com/webcasts.cfm under the "News and Events" section of the Company's website.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (NASDAQ:CYTX)(Frankfurt:XMPA) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Source: Business Wire
Related Articles
- Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
- Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine
- Stem Cells in Regenerative Medicine 2008 Market Report Focuses on the Various Clinical Applications of Different Types of Stem Cells
- First Patients Treated in Cytori's Stem & Regenerative Cell Heart Attack Study
- BrainStorm Cell Therapeutics' Adult Stem Cell Approach More Relevant Than Embryonic Stem Cell Therapies
- BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson's Disease
- MaxCyte is a Featured Speaker at 2nd International Stem Cells and Regenerative Medicine 2007
- Ortec Expands Focus to Stem Cell and Regenerative Medicine With Announcement of Letter of Intent to Acquire Hapto Biotech's Fibrin and Peptide Stem Cell and Cell Attachment Technologies
- Cytori Therapeutics Presents at Cell-Based Regenerative Medicine Symposium
- Using Pluripotent Germ Cells in Regenerative Medicine: An Ethical Alternative
 |
 |
User Comments (0)
RSS Feeds